Medicinal glaucoma therapy. What can we learn from large randomized clinical trials?
Jünemann A, Huchzermeyer C, Rejdak R (2013)
Publication Type: Journal article
Publication year: 2013
Journal
Book Volume: 110
Pages Range: 1134-48
Journal Issue: 12
DOI: 10.1007/s00347-012-2671-3
Abstract
The prospective multicenter randomized controlled clinical trials (RCTs) Ocular Hypertension Glaucoma Treatment Study (OHTS), Early Manifest Glaucoma Trial (EMGT), Advanced Glaucoma Intervention Study (AGIS), Collaborative Initial Glaucoma Treatment Study (CITGS) and Collaborative Normal Tension Glaucoma Study (CNGTS) are often named as landmarks for glaucoma management as the results of these studies provided the evidence for numerous therapeutic decisions in clinical practice. The studies confirmed the consensus that reduction of intraocular pressure reduces the risk of glaucoma progression covering the whole spectrum of glaucoma from ocular hypertension to advanced glaucoma. Furthermore, the identification of new risk factors allows a higher precision of assessment of the risk of progression. The RCTs achieved the main goal of high level of evidence, thus making progress in the understanding of glaucoma and its treatment and bridging consensus-based and evidence-based decisions. However, the implementation of the results into clinical practice needs adequate and accurate interpretation of the results.
Authors with CRIS profile
Involved external institutions
Poland (PL)How to cite
APA:
Jünemann, A., Huchzermeyer, C., & Rejdak, R. (2013). Medicinal glaucoma therapy. What can we learn from large randomized clinical trials? Ophthalmologe, 110(12), 1134-48. https://dx.doi.org/10.1007/s00347-012-2671-3
MLA:
Jünemann, Anselm, Cord Huchzermeyer, and R. Rejdak. "Medicinal glaucoma therapy. What can we learn from large randomized clinical trials?" Ophthalmologe 110.12 (2013): 1134-48.
BibTeX: Download